利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

38 条记录 (耗时 0.031 秒)

    Platform for connecting medical information to services for medical care
    31.
    发明授权
    Platform for connecting medical information to services for medical care 有权
    将医疗信息连接到医疗服务的平台

    公开(公告)号：US08700424B2

    公开(公告)日：2014-04-15

    申请号：US12630696

    申请日：2009-12-03

    申请人： Peter Hudson ,  Wayne Guerra

    发明人： Peter Hudson ,  Wayne Guerra

    IPC分类号： G06Q10/00 ,  G06Q50/00

    CPC分类号： G06F19/345 ,  G06F19/00 ,  G06F19/324 ,  G06F19/328 ,  G06F19/3481 ,  G06Q10/06 ,  G06Q40/00 ,  G06Q50/22 ,  G16H40/20 ,  G16H50/20

    摘要： A user device for connecting symptom, disease, procedure, and facility based information into actionable services for medical care and cost analysis is presented. The user device may include the functionality of linking medical information and providing user specific information. The user-specific information allows the user to make an informed decision about medical treatment. The user device may further be operative to tailor information in light of user characteristics such as location or healthcare network membership.

    摘要翻译： 提出了一种用于将症状，疾病，程序和设施信息连接到用于医疗保健和成本分析的可操作服务中的用户设备。 用户设备可以包括链接医疗信息和提供用户特定信息的功能。 用户特定信息允许用户作出关于医疗的知情决定。 用户设备还可以根据用户特征（例如位置或医疗保健网络成员资格）进行操作以定制信息。

    Condensed azepines as vasopressin agonists
    33.
    发明申请
    Condensed azepines as vasopressin agonists 审中-公开
    浓缩吖庚因作为血管加压素激动剂

    公开(公告)号：US20080261951A1

    公开(公告)日：2008-10-23

    申请号：US12213651

    申请日：2008-06-23

    申请人： Doreen Mary Ashworth ,  Gary Robert William Pitt ,  Peter Hudson ,  Christopher Martyn Yea ,  Richard Jeremy Franklin

    发明人： Doreen Mary Ashworth ,  Gary Robert William Pitt ,  Peter Hudson ,  Christopher Martyn Yea ,  Richard Jeremy Franklin

    IPC分类号： C07D403/12 ,  C07D495/04 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61P13/00

    CPC分类号： C07D403/12 ,  C07D413/12 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04

    摘要： This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V1 and V2 are both H, OMe or F, or one of V1 and V2 is Br, Cl, F, OH, OMe, OBn, OPh, O-acyl, N3, NH2, NHBn or NH-acyl and the other is H, or V1 and V2 together are ═O, —O(CH2)pO— or —S(CH2)S—; W1 is either O or S; X1 and X2 are both H, or together are ═O or ═S; Y is OR5 or NR6R7; R1, R2, R3 and R4 are independently selected from H, lower alkyl, lower alkyloxy, F, Cl and Br; R5 is selected from H and lower alkyl; R6 and R7 are independently selected from H and lower alkyl, or together are —(CH2)n—; n=3, 4, 5, 6; and p is 2 or 3. The compounds are agonists at the vasopressin V2 receptor and are useful as antidiuretics and procoagulants. The invention further comprises pharmaceutical compositions incorporating these vasopressin agonists, which compositions are particularly useful in the treatment of central diabetes insipidus, nocturnal enuresis and nocturia.

    摘要翻译： 本发明提供了根据通式（1）的新化合物，其中A是双环或三环吖庚因衍生物，V 1和V 2均为H，OMe或F，或 V 1和V 2之一是Br，Cl，F，OH，OMe，OBn，OPh，O-酰基，N 3， NH 2，NHBn或NH-酰基，另一个是H，或V 1和V 2一起是-O，-O（CH O-或-S（CH 2 CH 2）S - ; O 1或O 2是O或S; X 1和X 2均为H或一起为-O或-S; Y是OR 5或NR 6 R 7; R 1，R 2，R 3和R 4独立地选自H，低级烷基，低级烷氧基 ，F，Cl和Br; R 5选自H和低级烷基; R 6和R 7独立地选自H和低级烷基，或者一起是 - （CH 2）n - ; n = 3,4,5,6; p是2或3.化合物是加压素V2受体的激动剂，可用作抗利尿剂和促凝剂。 本发明还包括掺入这些加压素激动剂的药物组合物，该组合物特别可用于治疗中枢性尿崩症，夜间遗尿和夜尿症。

    In vivo affinity maturation scheme
    36.
    发明申请
    In vivo affinity maturation scheme 审中-公开
    体内亲和力成熟方案

    公开(公告)号：US20060099611A1

    公开(公告)日：2006-05-11

    申请号：US11156014

    申请日：2005-06-17

    申请人： Robert Irving ,  Peter Hudson ,  Huseyin Mustafa ,  Kim Wark ,  Matias Abregu

    发明人： Robert Irving ,  Peter Hudson ,  Huseyin Mustafa ,  Kim Wark ,  Matias Abregu

    IPC分类号： C12Q1/68 ,  C12P21/06 ,  C12N1/21 ,  C12N1/18 ,  C12N5/06

    CPC分类号： C40B40/02 ,  C12N15/102 ,  C12N15/1037

    摘要： The present invention relates to the field of evolution of nucleic acids in vivo and provides methods and compositions for introducing diversity into gene products. The present invention allows generation of new sequences that have desirable properties by virtue of high frequency mutation events within a cell. The high frequency mutation of a polynucleotide sequence results in, the production of a large population of new sequence variants. Appropriate selection and/or screening permits identification and isolation of mutant forms of the polynucleotide sequence as well as products resulting from expression of the mutant sequences.

    摘要翻译： 本发明涉及体内核酸进化领域，并提供了将多样性引入基因产物的方法和组合物。 本发明允许通过细胞内的高频突变事件产生具有期望特性的新序列。 多核苷酸序列的高频突变导致大量新序列变体的产生。 适当的选择和/或筛选允许鉴定和分离突变形式的多核苷酸序列以及由突变序列的表达产生的产物。